Golden Throat (06896.HK) announced that for the six months ended June 30, 2024, the group's revenue increased by approximately 9.4% to approximately RMB 0.52 billion. The profit attributable to equity holders of the company increased by approximately 9.9% to approximately RMB 0.134 billion for the six months ended June 30, 2023. The board of directors does not recommend declaring any interim dividends for the six months ended June 30, 2024.

The increase in group income was mainly due to the increase in sales of Golden Throat Lozenges (OTC) in the first half of 2024. For the six months ended June 30, 2024, the revenue from the sales of Golden Throat Lozenges (OTC) was approximately RMB 0.478 billion, a year-on-year increase of approximately 11.7%.